Abstract
Magnesium aspartate hydrochloride (MgAH) (Magnesiocard, Ciba-Geigy, Summit, NJ, USA) is a magnesium compound designed for oral administration in the treatment of magnesium deficiency. The intent of this randomised trial was to determine if MgAH is able to prevent and/or replenish the cisplatin-induced loss of body stores of magnesium
Highlights
Patients completing all planned cycles ofchemotherapy who had all planned serum magnesium determinations are included in this analysis
Since severe hypomagnesaemia can lead to clinically significant morbidity we analysed frequency of hypomagnesaemia
There were only two documentations of a magnesium level
Summary
Patients completing all planned cycles ofchemotherapy who had all planned serum magnesium determinations are included in this analysis. Group B than in group A, but this difference was not statistically significant. Since severe hypomagnesaemia can lead to clinically significant morbidity we analysed frequency of hypomagnesaemia
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
